AbbVie (ABBV) Stock Buyback History
TTM buyback yield 0.39% · Shareholder yield (TTM) 0.39%.
ABBV
TTM buyback yield
0.39%
Shareholder yield (TTM)
0.39%
5Y share count change
6.0%
TTM buyback spend
$1.51B
SBC coverage (TTM)
1.52x
YoY change in spend
-42.6%
5Y CAGR of spend
+0.0%
Peak year (2018)
$12.01B
Cumulative spend
$36.72B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- AbbVie (ABBV) repurchased about $1.51B of stock over the trailing twelve months.
- Diluted share count is up 6.0% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 1.52× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +0.0% per year over the latest 5-year window.
- TTM repurchases used about 17% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $980.00M | $955.00M | $25.00M | 1.77B | 0.1% | 0.24% |
| 2024 | $1.71B | $911.00M | $797.00M | 1.77B | 0.0% | 0.54% |
| 2023 | $1.97B | $747.00M | $1.23B | 1.77B | -0.3% | 0.72% |
| 2022 | $1.49B | $671.00M | $816.00M | 1.78B | 0.1% | 0.52% |
| 2021 | $934.00M | $692.00M | $242.00M | 1.78B | 6.2% | 0.39% |
| 2020 | $978.00M | $753.00M | $225.00M | 1.67B | 12.7% | 0.52% |
| 2019 | $629.00M | $430.00M | $199.00M | 1.48B | -4.0% | 0.48% |
| 2018 | $12.01B | $421.00M | $11.59B | 1.55B | -3.6% | 8.80% |
| 2017 | $1.41B | $365.00M | $1.04B | 1.60B | -1.7% | 0.92% |
| 2016 | $6.03B | $353.00M | $5.68B | 1.63B | -0.4% | 6.05% |
| 2015 | $7.59B | $282.00M | $7.30B | 1.64B | 1.7% | 7.95% |
| 2014 | $665.00M | $241.00M | $424.00M | 1.61B | 0.4% | 0.64% |
| 2013 | $320.00M | $212.00M | $108.00M | 1.60B | 1.7% | 0.38% |
| 2012 | $0.00 | $187.00M | −$187.00M | 1.58B | -3.0% | — |
| 2011 | $0.00 | $162.98M | −$162.98M | 1.63B | 0.0% | — |
| 2010 | $0.00 | $167.00M | −$167.00M | 1.63B | 0.0% | — |
| 2009 | $0.00 | $156.72M | −$156.72M | 1.63B | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for AbbVie (ABBV) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for AbbVie (ABBV)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for AbbVie (ABBV)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $980.00M | -42.6% | -$728.00M | ||
| 2024 | $1.71B | -13.4% | -$264.00M | ||
| 2023 | $1.97B | +32.6% | +$485.00M | ||
| 2022 | $1.49B | +59.2% | +$553.00M | ||
| 2021 | $934.00M | -4.5% | -$44.00M | ||
| 2020 | $978.00M | +55.5% | +$349.00M | ||
| 2019 | $629.00M | -94.8% | -$11.38B | ||
| 2018 | $12.01B | +752.1% | +$10.60B | ||
| 2017 | $1.41B | -76.6% | -$4.62B | ||
| 2016 | $6.03B | -20.5% | -$1.55B | ||
| 2015 | $7.59B | +1040.8% | +$6.92B | ||
| 2014 | $665.00M | +107.8% | +$345.00M | ||
| 2013 | $320.00M | — | +$320.00M | ||
| 2012 | $0 | — | $0 | ||
| 2011 | $0 | — | $0 | ||
| 2010 | $0 | — | $0 | ||
| 2009 | $0 | — | — |
In 2025, AbbVie (ABBV) buyback spend totalled $980.00M – plunged 42.6% year-over-year.
AbbVie buyback spend has recorded the values shown across consecutive periods, with a +0.0% compound annual growth rate over 2020–2025 (5 years).
Between 2018 and 2025, AbbVie buyback spend plunged 91.8%, falling from $12.01B to $980.00M.
$12.01B stands as the all-time-high annual buyback spend, posted in 2018, against a low of $0 during 2009.
Among 8 Healthcare peers, AbbVie (ABBV) ranks 7th; the peer median for buyback spend is $3.55B.
AbbVie Buyback Spend 2025: $980.00M
AbbVie buyback spend in 2025 was $980.00M, plunged 42.6% below 2024.
AbbVie Buyback Spend 2024: $1.71B
AbbVie buyback spend in 2024 was $1.71B, declined 13.4% below 2023.
AbbVie Buyback Spend 2023: $1.97B
AbbVie buyback spend in 2023 was $1.97B, surged 32.6% from 2022.
AbbVie Buyback Spend 2022: $1.49B
AbbVie buyback spend in 2022 was $1.49B, surged 59.2% from 2021.
AbbVie Buyback Spend 2021: $934.00M
AbbVie buyback spend in 2021 was $934.00M.
See more financial history for AbbVie (ABBV).
Sector peers by buyback spend
Companies in the same sector as AbbVie, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Thermo Fisher Scientific (TMO) | $3.00B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 1.52×.
Capital allocation mix
How AbbVie splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $9.05B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from AbbVie's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does AbbVie buy back its own stock?
Yes, AbbVie (ABBV) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does AbbVie spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $1.51B (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is AbbVie's buyback yield?
TTM buyback yield is about 0.39% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is AbbVie's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.39% combined (TTM-based where available).
Is AbbVie diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has AbbVie's share count changed?
Diluted weighted average shares changed by about 6.0% over roughly five fiscal years (annual income statement data).
What is AbbVie's buyback spend?
Latest reported buyback spend for AbbVie (ABBV) is $1.51B (period ending March 31, 2026).
How has AbbVie buyback spend changed year-over-year?
AbbVie (ABBV) buyback spend changed -42.6% year-over-year on the latest annual filing.
What is the long-term growth rate of AbbVie buyback spend?
AbbVie (ABBV) buyback spend compound annual growth rate is +0.0% over the most recent 5 years available.
When did AbbVie buyback spend hit its highest annual value?
AbbVie buyback spend reached its highest annual value of $12.01B in 2018.
What was AbbVie buyback spend in 2024?
AbbVie (ABBV) buyback spend in 2024 was $1.71B.
What was AbbVie buyback spend in 2025?
AbbVie (ABBV) buyback spend in 2025 was $980.00M.
Explore more
ABBV Overview
Company profile, financial tools, and key metrics
ABBV Revenue Counter
Earns $1,992 every second. See per minute, hour, and day.
ABBV Earnings Counter
Earns $115.39 per second net profit. See per minute, hour, and day.
ABBV Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
ABBV What If Invested
What if you had invested $1,000? See historical returns from any date.
ABBV How It Makes Money
Discover visual breakdown of $62.82B in revenue — where it comes from and where it goes.
ABBV Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ABBV Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ABBV Daily Price Character
Steady · 53.5% historical win rate (green days). Streaks & record days.
ABBV Dividend Profile
Yield: 3.17%. Safety: 4/8. See full history.
ABBV Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
ABBV Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
ABBV Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
ABBV Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.